octocog alfa




Firma Chun Cheong
Concise Prescribing Info
Octocog alfa (recombinant human coagulation factor VIII)
Treatment & prophylaxis of bleeding in patients w/ haemophilia A (congenital factor VIII deficiency).
Dosage/Direction for Use
IV On demand treatment: Early haemarthrosis, muscle or oral bleeding 20-40% or IU/dL 12-24 hrly (8-24 hr for patients <6 yr) for at least 1 day, until bleeding episode is resolved or healing is achieved. More extensive haemarthrosis, muscle bleeding or haematoma 30-60% or IU/dL 12-24 hrly (8-24 hr for patients <6 yr) for 3-4 days or more until pain & acute disability are resolved. Life-threatening haemorrhages 60-100% or IU/dL 8-24 hrly (6-12 hr for patients <6 yr) until threat is resolved. Minor surgery (including tooth extraction) 30-60% or IU/dL 24 hrly (12-24 hr for patients <6 yr), at least 1 day, until healing is achieved. Major surgery 80-100% or IU/dL (pre- & post-op) 8-24 hrly (6-24 hr for patients <6 yr) until adequate wound healing, then continue therapy for at least another 7 days to maintain factor VIII activity of 30-60%. Prophylaxis 20-40 IU/kg at intervals of 2-3 days. Childn <6 yr 20-50 IU/kg 3-4 times wkly.
Hypersensitivity to octocog alfa, mouse or hamster proteins or any of the excipient.
Special Precautions
Discontinue use immediately if symptoms of hypersensitivity occur. Formation of neutralizing antibodies (inhibitors). Carefully monitor patients for the development of inhibitors. Catheter-related complications if central venous access device (CVAD) is required. Patients on a controlled Na diet. Pregnancy & lactation.
Adverse Reactions
Development of factor VIII inhibitors, headache, fever.
MIMS Class
ATC Classification
B02BD02 - coagulation factor VIII ; Belongs to the class of blood coagulation factors. Used in the treatment of hemorrhage.
Advate powd for inj 250 IU
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in